# Observational Study on the Efficacy, Safety, and Tolerability of GAlcanezumab in Real Life Migraine Patients in ITaly

> **NCT04803513** · — · UNKNOWN · sponsor: **Campus Bio-Medico University** · enrollment: 300 (estimated)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Galcanezumab

## Key facts

- **NCT ID:** NCT04803513
- **Lead sponsor:** Campus Bio-Medico University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-01
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-08-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2021-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04803513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04803513, "Observational Study on the Efficacy, Safety, and Tolerability of GAlcanezumab in Real Life Migraine Patients in ITaly". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04803513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*